---
schema_version: "secwatch.filing_event.v1"
accession: "0001683168-25-003237"
form_type: "8-K"
ticker: "PHIO"
cik: "0001533040"
company_name: "Phio Pharmaceuticals Corp."
filed_at: "2025-05-07T23:59:59+00:00"
generated_at: "2026-05-22T07:55:18.061305+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Phio Pharmaceuticals reports complete pathologic response in 2 of 3 patients in third cohort of INTASYL PH-762 trial

## Summary
- 2 of 3 cSCC patients in Cohort 3 achieved 100% tumor clearance; third patient had <50% clearance.
- Across 10 patients in Cohorts 1-3: 4 complete responses, 1 near complete (>90%), 1 partial (>50%).
- No dose-limiting toxicities or clinically relevant adverse effects reported; PH-762 well tolerated.
- Fourth cohort enrolling; Phio expects to complete trial enrollment in Q3 2025.

## SEC filing metadata
- accession: 0001683168-25-003237
- form_type: 8-K
- ticker: PHIO
- cik: 0001533040
- company_name: Phio Pharmaceuticals Corp.
- filed_at: 2025-05-07T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1533040/000168316825003237/0001683168-25-003237-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1533040/000168316825003237/phio_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001683168-25-003237
- JSON: https://secwatch.observer/filing/0001683168-25-003237.json
- Plain text: https://secwatch.observer/filing/0001683168-25-003237.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.